ExonHit Partners with French Institute on Breast Cancer MDx | GenomeWeb

NEW YORK (GenomeWeb News) – ExonHit Therapeutics today said that it has licensed from Institut Gustave Roussy exclusive, worldwide rights to a tissue-based breast cancer signature that will developed into an assay.

Paris-based ExonHit plans to validate IGR's signature in a larger population and will have access to samples from IGR's biobank. The firm intends to launch a research-use-only test within 12 months. Following further validation, it intends to launch a clinical diagnostic assay based on the signature.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.